Jun 27 2025 This Week in Cardiology

This Week in Cardiology

Medscape Podcasts

Cardiology, Science, Medicalpractice, Electrophysiologist, Medscape, Internalmedicine, Medicaldecisionmaking, Expertcommentary, Eartrhythmdisorder, Health, Perspective, Medicine, Healthnews, Medicalexpert, Endoflifecare, Clinicaltrials, Health & Fitness

4.9 • 876 Ratings

🗓️ 27 June 2025

⏱️ 29 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

FDA approves triple-drug polypill, a change of opinion, a deep dive into invasive pulmonary embolism therapies, heart disease trends, and diabetes care is on fire are the topics John Mandrola, MD, discusses in this week's podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I FDA News in HTN

FDA announcement https://george-medicines.com/george-medicines-announces-fda-approval-of-widaplik-telmisartan-amlodipine-and-indapamide-a-new-single-pill-combination-treatment-for-hypertension-in-adults-including-initial-treatment/
Lancet Study https://doi.org/10.1016/S0140-6736(24)01744-6
JACC study vs placebo https://www.jacc.org/doi/abs/10.1016/j.jacc.2024.08.025
JAMA Cardiology Meta-analysis https://jamanetwork.com/journals/jamacardiology/fullarticle/2804313

II Invasive PE Therapy

EHJ-Open review: https://academic.oup.com/ehjopen/article/5/3/oeaf071/8156689

PEITHO Trial https://www.nejm.org/doi/10.1056/NEJMoa1302097
REAL PE Observational Study https://pmc.ncbi.nlm.nih.gov/articles/PMC11308131/

III Heart Disease Trends

King et al https://www.ahajournals.org/doi/10.1161/JAHA.124.038644

IV Diabetes Coverage

Medscape Link https://www.medscape.com/viewcollection/37830

You may also like:

The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact [email protected]

Transcript

Click on a timestamp to play from that location

0:00.0	You're listening to This Week in Cardiology from the heart.org, Medscape Cardiology.
0:05.4	This podcast is intended for health care professionals only.
0:08.8	Any views expressed are the presenters own and do not necessarily reflect the views of WebMD or Medscape.
0:15.2	Hi, everyone.
0:16.6	This is John Mandrola from the Heart.org Medscape Cardiology, and this is this week in cardiology for June 27, 2025.
0:26.0	This week, FDA approves triple drug polypill. My opinion has changed on the polypill.
0:33.0	A deep dive into invasive PE therapies, heart disease trends, and diabetes care is on fire.
0:41.5	First, an announcement. Next Friday is our Independence Day holiday. It's one of my favorite
0:47.5	holidays. This week in cardiology will therefore return on July 11th. Also, next weekend is the start of the Tour de France,
0:55.5	and even if you don't love professional cycling, this year could be one of the best ever races,
1:00.7	as three of the best cyclists in the world come to the race fit and healthy, and I can't wait
1:06.0	to watch. The second announcement is a sad one. I learned this week that fellow medical conservative Dr. Andrew Flappen of Edinburgh died suddenly.
1:17.4	Andrew invited me to speak twice at the Royal College meeting.
1:21.5	I have enjoyed my time with him immensely.
1:24.0	He was a force of nature and a doctor's doctor.
1:27.4	To my colleagues in Edinburgh,
1:29.2	I offer my condolences. Okay, first topic is FDA news in hypertension. The FDA this week
1:37.5	approved the three-component polypill for hypertension. Its brand name is going to be called
1:43.7	WIDAPL,
1:45.0	which is a really silly name. I can't even hardly pronounce it.
1:49.0	The polypill includes an ARB telmosartin, the calcium channel blocker amelotapine,
1:54.0	and the diuretic endipamide. There will be a standard dose pill with the standard doses of the three drugs, but there's also
	...

Please login to see the full transcript.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from Medscape Podcasts, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of Medscape Podcasts and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.